<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5269">
  <stage>Registered</stage>
  <submitdate>4/01/2015</submitdate>
  <approvaldate>4/01/2015</approvaldate>
  <nctid>NCT02335164</nctid>
  <trial_identification>
    <studytitle>A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults</studytitle>
    <scientifictitle>A Randomised, Controlled, Blinded Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian H5 Influenza Vaccine in Adults</scientifictitle>
    <utrn />
    <trialacronym>FLU003</trialacronym>
    <secondaryid>FLU003</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Influenza</healthcondition>
  </conditions>
  <interventions>
    <interventions>Other interventions - recombinant influenza hemagglutinin
Other interventions - Advax1
Other interventions - Advax2

Experimental: HA 45ug - recombinant influenza hemagglutinin (H5) 45ug, i.m. injection, 2 doses

Experimental: HA 45ug+Advax1 - recombinant influenza hemagglutinin(H5) 45ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses

Experimental: HA 45ug+Advax2 - recombinant influenza hemagglutinin (H5) 45ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses

Experimental: HA 15ug+Advax1 - recombinant influenza hemagglutinin (H5) 15ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses

Experimental: HA 15ug+Advax2 - recombinant influenza hemagglutinin (H5) 15ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses

Experimental: HA 5ug+Advax1 - recombinant influenza hemagglutinin (H5) 5ug, Advax1 adjuvant 20mg, i.m. injection, 2 doses

Experimental: HA 5ug+Advax2 - recombinant influenza hemagglutinin (H5) 5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses

Experimental: HA 2.5ug+Advax2 - recombinant influenza hemagglutinin (H5) 2.5ug, Advax2 adjuvant 20mg, i.m. injection, 2 doses

Experimental: HA 15ug - recombinant influenza hemagglutinin (H5) 15ug, i.m. injection, 2 doses


Other interventions: recombinant influenza hemagglutinin
recombinant influenza hemagglutinin

Other interventions: Advax1
Delta inulin adjuvant formulation 1

Other interventions: Advax2
Delta inulin adjuvant formulation 2

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The incidence of adverse events - The frequency of adverse events will be compared between groups</outcome>
      <timepoint>12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Hemagglutination inhibition assay - Seroconversion, seroprotection and GMT fold increase will be compared between groups at each time point using hemagglutination inhibition titers</outcome>
      <timepoint>1 month post each immunization and 11 months post final immunization</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Ambulatory males or females aged 18 years and over

          -  Able to provide written informed consent

          -  Willing and able to comply with the protocol for the duration of the study.

          -  Not planning to have seasonal influenza vaccine within 2 months from the time of the
             first trial immunization</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Pregnant or lactating women.

          -  Women of childbearing potential unless using a reliable and appropriate contraceptive
             method.

          -  Receipt of another investigational agent within 28 days preceding initiation of
             treatment.

          -  Any other serious medical, social or mental condition which, in the opinion of the
             investigator, would be detrimental to the subjects or the study.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/07/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>270</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2017</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA</recruitmentstate>
    <hospital>Flinders University - Adelaide</hospital>
    <postcode>5042 - Adelaide</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Vaxine Pty Ltd</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Flinders University</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Australian Respiratory and Sleep Medicine Institute</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Recombinant hemagglutinin has been shown to induce protective neutralising antibodies against
      avian influenza virus but is relatively non-immunogenic. An ideal pandemic avian influenza
      influenza vaccine would combine hemagglutinin antigen with an appropriate adjuvant to
      increase its immunogenicity. This Phase 1 study will collect preliminary human safety and
      efficacy data on combined formulations of recombinant hemagglutinin with Advax adjuvant
      formulations administered by intramuscular injection</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02335164</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dimitar Sajkov, FRACP, PhD</name>
      <address>Flinders Medical Centre</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Nikolai Petrovsky, FRACP, PhD</name>
      <address />
      <phone>0882044572</phone>
      <fax />
      <email>petr0071@flinders.edu.au</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>